|
1
|
Bismuth H, Nakache R and Diamond T:
Management strategies in resection for hilar cholangiocarcinoma.
Ann Surg. 215:31–38. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim J and Park C: Pathology of
cholangiocarcinoma. Abdom Imaging. 29:540–547. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan SA, Toledano MB and Taylor-Robinson
SD: Epidemiology, risk factors, and pathogenesis of
cholangiocarcinoma. HPB (Oxford). 10:77–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan SA, Davidson BR, Goldin R, Pereira
SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC,
Thursz MR and Wasan H; British Society of Gastroenterology, :
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
Consensus document. Gut. 51 Suppl 6:VI1–VI9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al: Guidelines for the diagnosis and
treatment of cholangiocarcinoma: An update. Gut. 61:1657–1669.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Knol JA and Pelletier SJ: Primary
Carcinomas of the Liver. Surgical treatment: Resection and
transplantation. Cambridge University Press; Cambridge: pp.
177–194. 2009
|
|
8
|
Hawley SA, Ross FA, Chevtzoff C, Green KA,
Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM and
Hardie DG: Use of cells expressing γ subunit variants to identify
diverse mechanisms of AMPK activation. Cell Metab. 11:554–565.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Algire C, Amrein L, Bazile M, David S,
Zakikhani M and Pollak M: Diet and tumor LKB1 expression interact
to determine sensitivity to anti-neoplastic effects of metformin in
vivo. Oncogene. 30:1174–1182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Memmott RM, Mercado JR, Maier CR, Kawabata
S, Fox SD and Dennis PA: Metformin prevents tobacco
carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila).
3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pyo JO, Yoo SM and Jung YK: The interplay
between autophagy and aging. Diabates Metab J. 37:333–339. 2013.
View Article : Google Scholar
|
|
13
|
Shackelford DB, Abt E, Gerken L, Vasquez
DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS
and Shaw RJ: LKB1 inactivation dictates therapeutic response of
non-small cell lung cancer to the metabolism drug phenformin.
Cancer Cell. 23:143–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davidson MB and Peters AL: An overview of
metformin in the treatment of type 2 diabetes mellitus. Am J Med.
102:99–110. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Z, Ren L, Liu C, Xia T, Zha X and Wang
S: Phenformin induces cell cycle change, apoptosis, and
mesenchymal-epithelial transition and regulates the
AMPK/mTOR/p70s6k and MAPK/ERK pathways in breast cancer cells. PloS
One. 10:e01312072015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Muñoz-Pinedo C, El Mjiyad N and Ricci JE:
Cancer metabolism: Current perspectives and future directions. Cell
Death Dis. 3:e2482012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shaw RJ: Glucose metabolism and cancer.
Curr Opin Cell Biol. 18:598–608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: Metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Zhang K, Wang J, Wu X, Liu X, Li
B, Zhu Y, Yu Y, Cheng Q, Hu Z, et al: Underexpression of LKB1 tumor
suppressor is associated with enhanced Wnt signaling and malignant
characteristics of human intrahepatic cholangiocarcinoma.
Oncotarget. 6:18905–18920. 2015.PubMed/NCBI
|
